Sangeetha Palakurthi

6.3k total citations
22 papers, 931 citations indexed

About

Sangeetha Palakurthi is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Sangeetha Palakurthi has authored 22 papers receiving a total of 931 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 11 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Sangeetha Palakurthi's work include Cancer Mechanisms and Therapy (4 papers), RNA modifications and cancer (4 papers) and PARP inhibition in cancer therapy (4 papers). Sangeetha Palakurthi is often cited by papers focused on Cancer Mechanisms and Therapy (4 papers), RNA modifications and cancer (4 papers) and PARP inhibition in cancer therapy (4 papers). Sangeetha Palakurthi collaborates with scholars based in United States, Switzerland and Norway. Sangeetha Palakurthi's co-authors include José A. Halperin, Hüseyin Aktaş, Richard M. Mortensen, Rudolf Flückiger, Juan Antonio Torres Acosta, Hüseyin Aktaş, Joyce F. Liu, Paul T. Kirschmeier, Ursula A. Matulonis and Ronny Drapkin and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Sangeetha Palakurthi

22 papers receiving 905 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sangeetha Palakurthi United States	11	654	278	237	162	65	22	931
Xiao-Feng Le United States	21	910 1.4×	462 1.7×	274 1.2×	111 0.7×	99 1.5×	23	1.3k
Xiaohua Leng China	13	1.2k 1.8×	183 0.7×	416 1.8×	145 0.9×	59 0.9×	15	1.5k
Pierosandro Tagliaferri Italy	17	627 1.0×	308 1.1×	229 1.0×	92 0.6×	38 0.6×	36	983
Karolina Sterzyńska Poland	18	428 0.7×	325 1.2×	226 1.0×	101 0.6×	68 1.0×	36	811
Hui Xing China	22	768 1.2×	343 1.2×	387 1.6×	122 0.8×	72 1.1×	54	1.2k
Linjie Zhao China	20	781 1.2×	250 0.9×	428 1.8×	192 1.2×	56 0.9×	37	1.2k
Karolina Wojtowicz Poland	16	572 0.9×	445 1.6×	246 1.0×	116 0.7×	80 1.2×	25	930
Cecilia J. Proietti Argentina	22	691 1.1×	689 2.5×	298 1.3×	191 1.2×	57 0.9×	37	1.3k
Jun-Ying Zhou United States	11	584 0.9×	186 0.7×	181 0.8×	111 0.7×	51 0.8×	11	749
Giacomo Cossa Italy	17	650 1.0×	352 1.3×	148 0.6×	72 0.4×	113 1.7×	26	926

Countries citing papers authored by Sangeetha Palakurthi

Since Specialization

Citations

This map shows the geographic impact of Sangeetha Palakurthi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sangeetha Palakurthi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sangeetha Palakurthi more than expected).

Fields of papers citing papers by Sangeetha Palakurthi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sangeetha Palakurthi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sangeetha Palakurthi. The network helps show where Sangeetha Palakurthi may publish in the future.

Co-authorship network of co-authors of Sangeetha Palakurthi

This figure shows the co-authorship network connecting the top 25 collaborators of Sangeetha Palakurthi. A scholar is included among the top collaborators of Sangeetha Palakurthi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sangeetha Palakurthi. Sangeetha Palakurthi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Donahue, Renee N., Madan Katragadda, Wei Huang, et al.. (2023). A T cell receptor β chain–directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity. Science Translational Medicine. 15(724). eadi0258–eadi0258. 10 indexed citations

Wu, Tinghui, et al.. (2023). A phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma and other solid tumor types known for association with the MYC oncogene (MYCHELANGELO I).. Journal of Clinical Oncology. 41(4_suppl). TPS627–TPS627. 8 indexed citations

Ogino, Atsuko, Jihyun Choi, Margaret K. Wilkens, et al.. (2020). Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations. Molecular Oncology. 15(1). 27–42. 16 indexed citations

Parmar, Kalindi, Bose Kochupurakkal, Jean‐Bernard Lazaro, et al.. (2019). The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition. Clinical Cancer Research. 25(20). 6127–6140. 103 indexed citations

Zervantonakis, Ioannis K., Laura M. Selfors, Sangeetha Palakurthi, et al.. (2019). Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. Molecular Cancer Therapeutics. 18(3). 642–655. 36 indexed citations

Miret, Juan J., Paul T. Kirschmeier, Shohei Koyama, et al.. (2019). Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity. Journal for ImmunoTherapy of Cancer. 7(1). 32–32. 108 indexed citations

Zervantonakis, Ioannis K., Hsing‐Yu Chen, Laura M. Selfors, et al.. (2017). Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. Nature Communications. 8(1). 365–365. 44 indexed citations

Ivanova, Elena V., Amir Reza Aref, Patrick H. Lizotte, et al.. (2017). Abstract LB-218: Validation of a novel microfluidic device for screening of immune checkpoint inhibitors using 3D organotypic tumor spheroids. Cancer Research. 77(13_Supplement). LB–218. 1 indexed citations

Izar, Benjamin, Elizabeth H. Stover, Itay Tirosh, et al.. (2017). Abstract AP19: SINGLE–CELL RNA–SEQUENCING OF PATIENT–DERIVED OVARIAN CANCER CELLS AND PATIENT–DERIVED XENOGRAFT MODELS. Clinical Cancer Research. 23(11_Supplement). AP19–AP19. 1 indexed citations

10.

Zervantonakis, Ioannis K., Hsing‐Yu Chen, Sangeetha Palakurthi, et al.. (2016). Abstract 3843: Design of effective combination therapies for high-grade serous ovarian cancer using patient-derived xenograft models. Cancer Research. 76(14_Supplement). 3843–3843. 1 indexed citations

11.

Odedra, Rajesh, Sangeetha Palakurthi, Andrew Hughes, et al.. (2016). Antitumor activity of the WEE1 inhibitor AZD1775 as a monotherapy and in combination with the PARP inhibitor olaparib in patient-derived explant (PDX) models. European Journal of Cancer. 69. S142–S142. 3 indexed citations

12.

Wang, Suming, Anna Blois, Tina El Rayes, et al.. (2016). Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment. Science Translational Medicine. 8(329). 329ra34–329ra34. 50 indexed citations

13.

Konstantinopoulos, Panagiotis A., Sangeetha Palakurthi, Qing Zeng, et al.. (2016). In vivo synergism between PARP-inhibitor olaparib and HSP90-inhibitor AT13387 in high grade serous ovarian cancer patient derived xenografts.. Journal of Clinical Oncology. 34(15_suppl). e17045–e17045. 6 indexed citations

14.

Buglio, Daniela, Sangeetha Palakurthi, Kate F. Byth, et al.. (2012). Essential role of TAK1 in regulating mantle cell lymphoma survival. Blood. 120(2). 347–355. 50 indexed citations

15.

Keeton, Erika Krasnickas, Kristen McEachern, Marat Alimzhanov, et al.. (2012). Abstract 2796: Efficacy and biomarker modulation by AZD1208, a novel, potent and selective pan-Pim kinase inhibitor, in models of acute myeloid leukemia. Cancer Research. 72(8_Supplement). 2796–2796. 3 indexed citations

16.

Keeton, Erika Krasnickas, Sangeetha Palakurthi, Marat Alimzhanov, et al.. (2011). AZD1208, a Novel, Potent and Selective Pan PIM Kinase Inhibitor, Demonstrates Efficacy in Models of Acute Myeloid Leukemia. Blood. 118(21). 1540–1540. 8 indexed citations

17.

Toader, Dorin, Jamal Saeh, Sangeetha Palakurthi, et al.. (2008). Discovery of small molecule inhibitors of MAP3K7 (TAK1) that induce apoptosis of distinct subtypes of B-cell lymphoma cells. 68. 1292–1292. 1 indexed citations

18.

Palakurthi, Sangeetha, et al.. (2001). Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation.. PubMed. 61(16). 6213–8. 274 indexed citations

19.

Palakurthi, Sangeetha, Rudolf Flückiger, Arun Changolkar, et al.. (2000). Inhibition of translation initiation mediates the anticancer effect of the n-3 polyunsaturated fatty acid eicosapentaenoic acid.. PubMed. 60(11). 2919–25. 84 indexed citations

20.

Aktaş, Hüseyin, et al.. (1998). Depletion of intracellular Ca ²⁺ stores, phosphorylation of eIF2α, and sustained inhibition of translation initiation mediate the anticancer effects of clotrimazole. Proceedings of the National Academy of Sciences. 95(14). 8280–8285. 117 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact